Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia

Published on Mar 30, 2020in Cancers6.639
· DOI :10.3390/CANCERS12040832
Ilaria Maggio7
Estimated H-index: 7
(UNIBO: University of Bologna),
Lisa Manuzzi7
Estimated H-index: 7
(UNIBO: University of Bologna)
+ 3 AuthorsDavide Campana31
Estimated H-index: 31
(UNIBO: University of Bologna)
Sources
Abstract
Background: Neuroendocrine neoplasms are rare entities consisting of a heterogeneous group of tumors that can originate from neuroendocrine cells present in the whole body. Their different behavior, metastatic potential, and prognosis are highly variable, depending on site of origin, grade of differentiation, and proliferative index. The aim of our work is to summarize the current knowledge of immunotherapy in different neuroendocrine neoplasms and its implication in clinical practice. Results: Several studies evaluated the efficacy and safety of immunotherapy in neuroendocrine neoplasms, in any setting of treatment, alone or in combination. Studies led to approval in neuroendocrine neoplasia of the lung, in combination with chemotherapy as first-line treatment or as a single-agent in a third-line setting, and Merkel cell carcinoma as a single agent. Results in other settings have been disappointing so far. Conclusions: Immunotherapy seems a valid treatment option for high grade, poorly differentiated neoplasms. Future trials should explore the combination of immunotherapy with other agents, such as anti-angiogenic or other immunotherapy agents, in order to evaluate potential efficacy in low and intermediate grades, well differentiated tumors.
Download
📖 Papers frequently viewed together
References106
Newest
#1Ming Lu (PKU: Peking University)H-Index: 11
#2Panpan Zhang (PKU: Peking University)H-Index: 5
Last. Lin Shen (PKU: Peking University)H-Index: 34
view all 18 authors...
Purpose: Patients with recurrent or metastatic neuroendocrine neoplasms (NENs) had a poor prognosis and few treatment options. Toripalimab, a humanized IgG4 antibody specific for human PD-1 receptor, was first approved to treat 2nd line metastatic melanoma in China in 2018. Experimental Design: The multiple-center phase Ib trial enrolled patients with NENs (Ki-67≄10%) after failures of 1st line therapy to received 3 mg/kg toripalimab once every two weeks. The primary objective was objective resp...
Source
#1Daniel M. Halperin (University of Texas MD Anderson Cancer Center)H-Index: 14
#2Suyu Liu (University of Texas MD Anderson Cancer Center)H-Index: 16
Last. James C. Yao (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 18 authors...
619Background: Neuroendocrine tumors (NETs) are relatively rare and heterogeneous tumors arising throughout the aerodigestive tract, which are incurable and life-limiting when metastatic. Prior stu...
Source
#1Mark Lee (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
#2Robert M. Samstein (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 24
Last. Luc G. T. Morris (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 64
view all 5 authors...
ABSTRACTImmune checkpoint inhibitor (ICI) therapies can achieve meaningful tumor responses in a subset of patients with most types of cancer that have been investigated. However, the majority of pa...
Source
#1Daniel Morgensztern (WashU: Washington University in St. Louis)H-Index: 34
#2Benjamin BesseH-Index: 75
Last. David P. Carbone (OSU: Ohio State University)H-Index: 91
view all 16 authors...
Purpose: Although extensive-stage small cell lung cancer (SCLC) is highly responsive to first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting delta-like 3 protein (DLL3). This open-label, single-arm, Phase II study (TRINITY) assessed safety and efficacy of Rova-T in patients with DLL3-expressing SCLC in the third-line and beyond (3L+) setting. Experimental Design: Patients with DLL3-expressing S...
Source
#1Luis Paz-Ares (Complutense University of Madrid)H-Index: 84
#2M. DvorkinH-Index: 5
Last. J.H. Ji (SKKU: Sungkyunkwan University)H-Index: 7
view all 228 authors...
Summary Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum–etoposide) in treatment-naive patients with ES-SCLC. Methods This randomised, open-label, phase 3 trial was done at 20...
Source
#1Yu Jung Kim (Seoul National University Bundang Hospital)H-Index: 27
#2Bhumsuk Keam (SNU: Seoul National University)H-Index: 51
Last. Dae Seog Heo (SNU: Seoul National University)H-Index: 71
view all 12 authors...
Abstract Objective Patients with etoposide/platinum-refractory extensive disease (ED) small-cell lung cancer (SCLC) have a dismal prognosis. We aimed to evaluate the efficacy and safety of pembrolizumab and paclitaxel combination therapy in these patients. Methods In this multi-center, phase II study, ED-SCLC patients who showed progression after etoposide/platinum chemotherapy received paclitaxel 175 mg/m2 every 3 weeks for up to six cycles. Pembrolizumab 200 mg was added from the second cycle ...
Source
Abstract Background As a multicentre, randomized, double-blind phase II trial, ALTER 1202 (NCT03059797) suggests that anlotinib is a promising treatment option for patients with relapsed SCLC who failed ≄ 2 lines of chemotherapy. The median progress-free survival (PFS) was significantly longer in the anlotinib group compared with the placebo group (4.1 months vs 0.7 months; HR 0.19, 95% CI 0.12 to 0.32], P Methods Eligible either limited- or extensive-stage SCLC patients with disease progression...
Source
#1Francesco GelsominoH-Index: 20
#2Giuseppe LambertiH-Index: 11
Last. Andrea ArdizzoniH-Index: 69
view all 7 authors...
Abstract Small cell lung cancer (SCLC) was defined as a “recalcitrant cancer” because of its dismal prognosis and lack of outcome improvements in the last 30 years. Immunotherapy with checkpoint inhibitors revolutionized treatment in many cancer types and results from the IMpower133 study, a double-blind placebo-controlled phase III trial, showed overall survival benefit for atezolizumab when added to standard platinum-etoposide chemotherapy in first-line SCLC setting for the first time since ye...
Source
#1Jyoti Malhotra (RU: Rutgers University)H-Index: 17
#2Petros Nikolinakos (Gulf Coast Regional Blood Center)H-Index: 18
Last. Benjamin BesseH-Index: 75
view all 20 authors...
8516Background: Rovalpituzumab tesirine (Rova-Tℱ) is an antibody-drug conjugate targeting DLL3, a Notch ligand expressed in SCLC but not normal tissue. Nivo ± Ipi has activity in 2L+ SCLC. Prelimin...
Source
#1Anna Kathrin StĂŒven (CharitĂ©)H-Index: 1
#2Bertram Wiedenmann (Charité)H-Index: 114
// Anna Kathrin Stuven 1 and Bertram Wiedenmann 1 1 Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Campus Charite Mitte, Charite-Universitatsmedizin Berlin, Berlin, Germany Correspondence to: Anna Kathrin Stuven, email: anna-kathrin.stueven@charite.de Keywords : NET/NEC G2/3; pembrolizumab; immunotherapy; PD-L1 Received: September 26, 2018 Accepted: March 23, 2019 Published: May 14, 2019 Abstract Neuroendocrine neoplasms (NEN) are a heterogeneous group of tumors, whic...
Source
Cited By15
Newest
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumor of the skin whose incidence is rising. Multimodal treatment is crucial in the non-metastatic, potentially curable setting. However, the optimal management of patients with non-metastatic MCC is still unclear. In addition, novel insights into tumor biology and newly developed treatments (e.g., immune checkpoint inhibitors) that dramatically improved outcomes in the advanced setting are being investigated in earlier stages with prom...
Source
#1Giorgia GarganeseH-Index: 15
#2Alessia RomitoH-Index: 9
Last. Anna Fagotti (UCSC: Catholic University of the Sacred Heart)H-Index: 52
view all 4 authors...
PURPOSE OF REVIEW To provide the latest insight on the rare vulvar and vaginal malignancies, able to impact on clinical practice, and to outline new potential research developments. RECENT FINDINGS Many efforts are being made to produce technical and scientific advances in the fields of vulvar and vaginal carcinoma, including imaging work-up, interventional procedures and minimally invasive surgical approach, as well as molecular profiling and identification of new target treatments. SUMMARY In ...
Source
Background. Lung neuroendocrine tumors account for approximately 15% of all lung cancer cases. LNET are subdivided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small-cell lung cancer (SCLC). The Ki-67 index has been used for decades to evaluate mitotic counts however, the role of Ki-67 as a biomarker for assessing prognosis and guiding therapy in metastatic LNET still lacks feasible clinical validation. Recent clinical trials have indicat...
Source
#1Uli Fehrenbach (Charité)H-Index: 7
#2Siyi Xin (Charité)
Last. Tobias Penzkofer (Charité)H-Index: 22
view all 13 authors...
BACKGROUND Rapid quantification of liver metastasis for diagnosis and follow-up is an unmet medical need in patients with secondary liver malignancies. We present a 3D-quantification model of neuroendocrine liver metastases (NELM) using gadoxetic-acid (Gd-EOB)-enhanced MRI as a useful tool for multidisciplinary cancer conferences (MCC). METHODS Manual 3D-segmentations of NELM and livers (149 patients in 278 Gd-EOB MRI scans) were used to train a neural network (U-Net architecture). Clinical usef...
Source
#1Giovanni CentonzeH-Index: 12
#2Vincenzo LaganoH-Index: 2
Last. Massimo MilioneH-Index: 33
view all 19 authors...
High-grade Gastroenteropancreatic Neuroendocrine neoplasms (H-NENs) comprehend well-differentiated tumors (NET G3) and poorly differentiated carcinomas (NEC) with proliferative activity indexes as mitotic count (MC) >20 mitoses/10 HPF and Ki-67 >20%. At present, no specific therapy for H-NENs exists and the several evidences of microenvironment involvement in their pathogenesis pave the way for tailored therapies. Forty-five consecutive cases, with available information about T-cell, immune, and...
Source
#1Manuela AlbertelliH-Index: 15
#2Andrea Dotto (UniGe: University of Genoa)H-Index: 3
Last. Diego Ferone (UniGe: University of Genoa)H-Index: 69
view all 8 authors...
Immunotherapy, so promising in many neoplasms, still does not have a precise role in the treatment of neuroendocrine neoplasms (NENs). In this article, we provide an overview on the current knowledge about immunotherapy with immune checkpoint inhibitors (ICIs) applied to NENs, evaluating future perspectives in this setting of tumors.Evidence so far available for ICIs in gastroenteropancreatic (GEP)-NENs is definitively not as robust as for other tumors such as Small Cell Lung Cancer or Merkel Ce...
Source
#1Jasna Metovic (UNITO: University of Turin)H-Index: 9
#2Marco BarellaH-Index: 2
Last. Giuseppe Pelosi (University of Milan)H-Index: 70
view all 9 authors...
Neuroendocrine neoplasms of the lung (Lung NENs) encompass NE tumors (NETs), which are in turn split into typical and atypical carcinoids, and NE carcinomas (NECs), which group together small-cell ...
Source
Mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) are rare tumors composed of two different histological components, one of which is of a neuroendocrine origin. Given its suggested underdiagnosis and consequent low prevalence, no clear diagnostic and treatment guidelines are available, and treatment usually follows regimens similar to that of the most aggressive component. On the other hand, multiple primary tumors (MPTs) are also rare neoplastic entities that usually confer a challenge...
Source
#1Alejandro Garcia-Alvarez (Hebron University)H-Index: 1
#2Jorge Hernando Cubero (Hebron University)
Last. Jaume Capdevila (Hebron University)H-Index: 34
view all 3 authors...
OPINION STATEMENT Neuroendocrine neoplasms (NENs) constitute a heterogenous group of malignancies. Translational research into NEN cell biology is the cornerstone for drug development strategies in this field. Somatostatin receptor type 2 (SSTR2) expression is the hallmark of well-differentiated neuroendocrine tumors (NETs). Somatostatin analogs and peptide receptor radionuclide therapy (PRRT) form the basis of anti-SSTR2 treatment onto new combination strategies, antibody-drug conjugates and bi...
Source
#1Anja Rinke (University of Marburg)H-Index: 23
#2Christoph J. Auernhammer (LMU: Ludwig Maximilian University of Munich)H-Index: 31
Last. Thomas M. Gress (University of Marburg)H-Index: 82
view all 14 authors...
Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic a...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.